173 related articles for article (PubMed ID: 35946524)
1. Successful salvage therapy using high-dose furmonertinib (AST2818) for non-small-cell lung cancer after Osimertinib resistance: a case report.
Cheng D; Tang S; Li D; Zhao W; Wei W; Fang C; Ji M
Anticancer Drugs; 2022 Sep; 33(8):768-772. PubMed ID: 35946524
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
[TBL] [Abstract][Full Text] [Related]
3. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.
Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J
Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633
[TBL] [Abstract][Full Text] [Related]
4. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
5. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
[TBL] [Abstract][Full Text] [Related]
6. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
7. Acquired Resistance to Osimertinib in
Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
[TBL] [Abstract][Full Text] [Related]
8. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
9. Furmonertinib: First Approval.
Deeks ED
Drugs; 2021 Oct; 81(15):1775-1780. PubMed ID: 34528187
[TBL] [Abstract][Full Text] [Related]
10. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
11. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
[TBL] [Abstract][Full Text] [Related]
12. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K
Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
Hu X; Zhang S; Ma Z; Feng J; Wu L; Lv D; Zhou J; Zhang X; Liu L; Yu Q; Liao W; Zhang Y; Wang X; Cheng Y; Niu H; Wang Z; Wang D; Huang C; Liu C; Zhao H; Feng J; Li J; Ying K; Yang N; Qin S; Hu J; Liu F; Jiang Y; Ge N; Shi Y
BMC Med; 2023 Apr; 21(1):164. PubMed ID: 37118803
[TBL] [Abstract][Full Text] [Related]
14. Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.
Han ZJ; Luo N; Li L; Liu ZL
Ann Palliat Med; 2021 Jul; 10(7):8413-8419. PubMed ID: 33977727
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W
Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
20. Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib.
Makimoto G; Ohashi K; Senoo S; Hotta K; Maeda Y; Kiura K
Intern Med; 2019 Jun; 58(11):1625-1627. PubMed ID: 30713295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
